A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
Singh, Awadhesh Kumar, Sahay, Rakesh, Gil, Navneet, Tripathi, Sudhir, Khandelwal, Vipul, Basu, Indraneel, Shembalkar, Jayashree, Srivastava, Manoj Kumar, Bhatia, Girish, Pathak, Vaishali, Dange, Amol, Chaudhri, Mayura, Naskar, Arindam, Mondal, Ashish, Gangwal, Pawan, Kumar, Surendra, Kumar, Deepak, Raju, Yandrapati gnana sundara, Sorate, Sanket, Gavli, Onkar, Kumbalkar, Sunita, Varade, Deepak, Chaudhari, Harshal, Prasad, Durga, Patil, Manoj, Bhagwat, Nikhil, Agarwal, Rohit, Pandey, Arun, Ghosh, Soumya, Patil, Shubhashree, Kini, Vishal, Sharma, Akhilesh, Mayabhate, Mayur, Pawar, Roshan, Rajput, Aashish, Shahavi, Vinakaya
Published in International journal of diabetes in developing countries (01.03.2024)
Published in International journal of diabetes in developing countries (01.03.2024)
Get full text
Journal Article